4.4 Article

Diagnosis, Monitoring, and Treatment of Primary Ciliary Dyskinesia: PCD Foundation Consensus Recommendations Based on State of the Art Review

期刊

PEDIATRIC PULMONOLOGY
卷 51, 期 2, 页码 115-132

出版社

WILEY
DOI: 10.1002/ppul.23304

关键词

primary ciliary dyskinesia; PCD; kartagener; consensus statement; PCD Foundation

资金

  1. National Institutes of Health (NIH) [U54HL096458, 5R01HL071798]
  2. Genetic Disorders of Mucociliary Clearance is a part of the NCATS Rare Diseases Clinical Research Network (RDCRN) [U54HL096458]
  3. RDCRN is an initiative of the Office of Rare Diseases Research (ORDR), NCATS
  4. CTSA NIH/NCATS UNC [ULTR000083]
  5. CTSA NIH/NCATS Colorado [UL1TR000154]
  6. Intramural Research Program of NIH/NIAID

向作者/读者索取更多资源

Primary ciliary dyskinesia (PCD) is a genetically heterogeneous, rare lung disease resulting in chronic oto-sino-pulmonary disease in both children and adults. Many physicians incorrectly diagnose PCD or eliminate PCD from their differential diagnosis due to inexperience with diagnostic testing methods. Thus far, all therapies used for PCD are unproven through large clinical trials. This review article outlines consensus recommendations from PCD physicians in North America who have been engaged in a PCD centered research consortium for the last 10 years. These recommendations have been adopted by the governing board of the PCD Foundation to provide guidance for PCD clinical centers for diagnostic testing, monitoring, and appropriate short and long-term therapeutics in PCD patients. (C) 2015 The Authors. Pediatric Pulmonology Published by Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据